日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

The importance of methods for site performance evaluation in REPRIEVE, a longitudinal, global, multicenter trial

REPRIEVE 是一项纵向、全球、多中心试验,其研究中心绩效评估方法的重要性

Fulda, Evelynne S; Fichtenbaum, Carl J; Kileel, Emma M; Zanni, Markella V; Aberg, Judith A; Malvestutto, Carlos; Cardoso, Sandra Wagner; Berzins, Baiba; Lira, Rita; Harden, Regina; Robbins, Gregory; Martinez, Maria; Nieves, Sylvia Davila; McCallum, Sara; Cruz, Jorge Leon; Umbleja, Triin; Sprenger, Heather; Giguel, Francoise; Bone, Frederic; Wood, Ken; Byroads, Mark; Paradis, Kayla; Lu, Michael T; Douglas, Pamela S; Ribaudo, Heather J; Grinspoon, Steven K; Fitch, Kathleen V

Pharmacokinetics of tenofovir during pregnancy and postpartum

妊娠期和产后替诺福韦的药代动力学

Best, B M; Burchett, S; Li, H; Stek, A; Hu, C; Wang, J; Hawkins, E; Byroads, M; Watts, D H; Smith, E; Fletcher, C V; Capparelli, E V; Mirochnick, M

Pharmacokinetics of an increased atazanavir dose with and without tenofovir during the third trimester of pregnancy

妊娠晚期服用阿扎那韦(有或无替诺福韦)的药代动力学研究

Kreitchmann, Regis; Best, Brookie M; Wang, Jiajia; Stek, Alice; Caparelli, Edmund; Watts, D Heather; Smith, Elizabeth; Shapiro, David E; Rossi, Steve; Burchett, Sandra K; Hawkins, Elizabeth; Byroads, Mark; Cressey, Tim R; Mirochnick, Mark

The Irritable Bowel Syndrome Outcome Study (IBSOS): rationale and design of a randomized, placebo-controlled trial with 12 month follow up of self- versus clinician-administered CBT for moderate to severe irritable bowel syndrome

肠易激综合征结局研究(IBSOS):一项针对中重度肠易激综合征患者的自我认知行为疗法与临床医生实施的认知行为疗法的随机、安慰剂对照试验的原理和设计,随访时间为12个月。

Lackner, Jeffrey M; Keefer, Laurie; Jaccard, James; Firth, Rebecca; Brenner, Darren; Bratten, Jason; Dunlap, Laura J; Ma, Changxing; Byroads, Mark